Rockefeller Capital Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.32M | Buy |
47,787
+13,624
| +40% | +$1.14M | 0.01% | 1031 |
|
|
2026
Q1 | $2.74M | Sell |
34,163
-2,544
| -7% | -$210K | ﹤0.01% | 1160 |
|
|
2025
Q4 | $3.13M | Buy |
36,707
+922
| +3% | +$75.7K | 0.01% | 1062 |
|
|
2025
Q3 | $2.78M | Sell |
35,785
-6,828
| -16% | -$533K | 0.01% | 1032 |
|
|
2025
Q2 | $3.33M | Buy |
42,613
+3,550
| +9% | +$265K | 0.01% | 925 |
|
|
2025
Q1 | $2.83M | Sell |
39,063
-1,402
| -3% | -$100K | 0.01% | 909 |
|
|
2024
Q4 | $3.01M | Sell |
40,465
-174,262
| -81% | -$12.2M | 0.01% | 872 |
|
|
2024
Q3 | $14.2M | Sell |
214,727
-9,925
| -4% | -$721K | 0.04% | 435 |
|
|
2024
Q2 | $20.8M | Buy |
224,652
+13,027
| +6% | +$1.15M | 0.06% | 306 |
|
|
2024
Q1 | $20.2M | Buy |
211,625
+14,434
| +7% | +$1.21M | 0.06% | 323 |
|
|
2023
Q4 | $15M | Sell |
197,191
-19,350
| -9% | -$1.35M | 0.05% | 357 |
|
|
2023
Q3 | $15M | Sell |
216,541
-9,415
| -4% | -$757K | 0.06% | 325 |
|
|
2023
Q2 | $21.3M | Sell |
225,956
-41,642
| -16% | -$3.62M | 0.08% | 246 |
|
|
2023
Q1 | $22.1M | Buy |
267,598
+203,787
| +319% | +$16M | 0.1% | 235 |
|
|
2022
Q4 | $4.76M | Sell |
63,811
-262,234
| -80% | -$20.2M | 0.02% | 539 |
|
|
2022
Q3 | $26.9M | Sell |
326,045
-4,317
| -1% | -$415K | 0.14% | 160 |
|
|
2022
Q2 | $31.4M | Buy |
330,362
+2,601
| +0.8% | +$269K | 0.17% | 140 |
|
|
2022
Q1 | $38.6M | Buy |
327,761
+765
| +0.2% | +$85.8K | 0.19% | 126 |
|
|
2021
Q4 | $42.4M | Buy |
326,996
+6,434
| +2% | +$750K | 0.2% | 122 |
|
|
2021
Q3 | $36.3M | Sell |
320,562
-15,922
| -5% | -$1.82M | 0.19% | 129 |
|
|
2021
Q2 | $34.8M | Buy |
336,484
+13,673
| +4% | +$1.29M | 0.2% | 122 |
|
|
2021
Q1 | $27M | Buy |
322,811
+12,045
| +4% | +$1.02M | 0.18% | 132 |
|
|
2020
Q4 | $28.4M | Sell |
310,766
-24,359
| -7% | -$2.02M | 0.21% | 115 |
|
|
2020
Q3 | $26.7M | Sell |
335,125
-3,401
| -1% | -$265K | 0.25% | 101 |
|
|
2020
Q2 | $23.4M | Buy |
338,526
+9,579
| +3% | +$681K | 0.24% | 91 |
|
|
2020
Q1 | $20.7M | Sell |
328,947
-11,883
| -3% | -$857K | 0.27% | 81 |
|
|
2019
Q4 | $26.5M | Buy |
340,830
+1,239
| +0.4% | +$96.7K | 0.33% | 71 |
|
|
2019
Q3 | $24.9M | Buy |
339,591
+5,166
| +2% | +$363K | 0.34% | 67 |
|
|
2019
Q2 | $20.6M | Sell |
334,425
-9,645
| -3% | -$583K | 0.29% | 87 |
|
|
2019
Q1 | $21.9M | Buy |
344,070
+19,683
| +6% | +$1.12M | 0.31% | 77 |
|
|
2018
Q4 | $16.6M | Sell |
324,387
-6,420
| -2% | -$325K | 0.29% | 83 |
|
|
2018
Q3 | $19.2M | Buy |
330,807
+144
| +0% | +$7.04K | 0.29% | 88 |
|
|
2018
Q2 | $16M | Sell |
330,663
-70,662
| -18% | -$3.3M | 0.26% | 89 |
|
|
2018
Q1 | $18.7M | Buy |
+401,325
| New | +$17.4M | 0.31% | 83 |
|
Other funds holding EW
Rockefeller Capital Management's EW Position: Q2 2026 in Review
Rockefeller Capital Management increased its Edwards Lifesciences (EW) stake by 40% in Q2 2026, buying an estimated $1.14M and bringing the position to 47,787 shares worth $4.32M. The position accounts for 0.01% of the portfolio, ranked #1031.
Rockefeller Capital Management first reported a position in EW in Q1 2018 and has held it in 34 quarters since. The position peaked at $42.4M in Q4 2021. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Rockefeller Capital Management held 47,787 shares of Edwards Lifesciences worth $4.32M as of Q2 2026.
- Rockefeller Capital Management bought 13,624 Edwards Lifesciences shares in Q2 2026, an estimated $1.14M.
- Edwards Lifesciences made up 0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #1031 holding.
- Rockefeller Capital Management first reported a position in Edwards Lifesciences in Q1 2018 and has held it in 34 quarters since.
- Rockefeller Capital Management's Edwards Lifesciences position peaked at $42.4M in Q4 2021.
- 1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.